Therapeutic Management During Pregnancy and Relapse Risk in Women With Multiple Sclerosis.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gavoille Antoine, Rollot Fabien, Casey Romain, Mathey Guillaume, Le Page Emmanuelle, Ciron Jonathan, De Sèze Jérôme, Ruet Aurélie, Maillart Elisabeth, Labauge Pierre, Zephir Hélène, Kwiatkowski Arnaud, Papeix Caroline, Defer Gilles, Lebrun-Frenay Christine, Moreau Thibault, Laplaud David-Axel, Berger Eric, Dubessy Anne-Laure, Clavelou Pierre, Thouvenot Eric, Heinzlef Olivier, Pelletier Jean, Al-Khedr Abdullatif, Casez Olivier, Bourre Bertrand, Wahab Abir, Magy Laurent, Moulin Solène, Camdessanché Jean-Philippe, Doghri Inès, Sarov-Riviere Mariana, Hankiewicz Karolina, Pottier Corinne, Dos Santos Amélie, Nifle Chantal, Subtil Fabien, Vukusic Sandra, OFSEP Investigators
Аннотация
OBJECTIVE: To estimate the effect of DMT management during pregnancy on MS relapse rate and compare different therapeutic strategies.
DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter retrospective cohort study using data from January 1990 to December 2023. Data were extracted in December 2023 from the French MS registry. Among 52 955 women in the registry, we included pregnancies identified through childbirths in patients with relapsing-onset MS who were monitored for at least 18 months before delivery and 9 months after. Pregnancies occurring less than 18 months apart or with missing month of birth were excluded.
EXPOSURES: Mediation analysis was used to estimate the total, direct, and indirect (mediated by DMT management) effects of pregnancy. Different therapeutic strategies were compared: DMT interruption, switching to or maintaining interferon β or glatiramer acetate, switching to or maintaining natalizumab until the third trimester, and switching to or maintaining intravenous anti-CD20 and interrupting it 3 months before conception.
MAIN OUTCOMES AND MEASURES: The primary outcome was the annualized relapse rate (ARR) during the preconception, gestation, and postpartum periods. Within a causal inference framework, counterfactual ARRs were estimated using longitudinal g-computation, combining a random forest algorithm for predicting DMTs, and a mixed-effects Poisson model for relapses.
RESULTS: We included 6341 pregnancies occurring in 4998 women (mean [SD] age at conception, 31.5 [4.5] years). DMT management during pregnancy significantly increased ARR during gestation (causal rate ratio [cRR], 1.13; 95% CI, 1.06-1.22) and postpartum (cRR, 1.08; 95% CI, 1.01-1.16) periods. This led to a deleterious total effect of pregnancy on ARR, particularly in women receiving natalizumab before pregnancy with prolonged interruption (ie, interruption before the second trimester or resumption more than 3 months after delivery; cRR, 2.18; 95% CI, 1.76-2.69), and in women receiving fingolimod (cRR, 2.15; 95% CI, 1.60-2.93). Compared to DMT interruption, anti-CD20 strategy was the most effective (cRR, 0.38; 95% CI, 0.25-0.52), followed by the natalizumab strategy with short interruption (cRR, 0.80; 95% CI, 0.71-0.90), whereas interferon β (cRR, 0.93; 95% CI, 0.86-0.99) and glatiramer acetate strategies (cRR, 0.91; 95% CI, 0.84-0.99) were less effective.
CONCLUSION: In this study, DMT management during pregnancy significantly increased relapse risk, particularly in patients receiving natalizumab with prolonged interruption or fingolimod. The strategy based on the use of anti-CD20 before pregnancy was the most effective to mitigate this risk.